FDA approves high-dose Fluzone for older patients

12/23/2009 | Reuters

Sanofi Pasteur secured FDA approval to promote a high-dose formulation of its Fluzone seasonal flu vaccine for people 65 and older. Sanofi's application was supported by clinical data showing the superiority of high-dose Fluzone over its original formulation in eliciting an immune response.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT